Federal · CMS Medicare Drug Price Negotiation final rule, FR Doc. 2026-22792
Medicare drug price negotiation: CMS makes the program's rules permanent in federal regulations (effective Dec. 5, 2026; applies starting with 2029)
Final rule published Nov. 9, 2026 · Effective Dec. 5, 2026 · Applies starting 2029
Free. Nonpartisan. Unsubscribe anytime.
The short version
- The Medicare Drug Price Negotiation Program, created by the Inflation Reduction Act of 2022, lets Medicare negotiate prices ("maximum fair prices") for certain selected drugs with their manufacturers.
- Until now, CMS ran the program through guidance documents. This final rule writes those policies into federal regulations (a new 42 CFR part 429 and changes to part 423), with limited changes.
- New pieces include a policy for certain fixed-combination drugs that are new formulations, details on how drugs that lost orphan-drug status are counted, and how off-label use is considered when a drug is renegotiated.
- For Medicare Part D, the rule keeps the requirement that drug plans include selected drugs on their formularies once a maximum fair price is in effect.
- Unless otherwise stated, the rule applies starting with the 2029 price year; drugs picked for 2026 through 2028 stay under CMS's existing guidance. Nothing in the rule is specific to South Carolina.
- Status
- Final rule published Nov. 9, 2026 (91 FR 72176; FR Doc. 2026-22792). Effective December 5, 2026. The rules apply to the Negotiation Program starting with initial price applicability year 2029 and to Part D coverage beginning January 1, 2029. Drugs selected for 2026, 2027 and 2028 continue to follow CMS's existing program guidance until then.
- Official source
- Federal Register, 91 FR 72176 (Nov. 9, 2026), FR Doc. 2026-22792, Centers for Medicare & Medicaid Services, HHS, "Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program" (final rule, 42 CFR parts 423 and 429)
CMS: Medicare Drug Price Negotiation Program Final Guidance for Initial Price Applicability Year 2028 (Sept. 30, 2025)
This explainer does not take a side. It describes what the rule says, using the final rule text published in the Federal Register. The rule is long (about 215 Federal Register pages); this page covers the main points.
What the rule does
The Centers for Medicare & Medicaid Services (CMS) finalized a rule that “finalizes and codifies the Medicare Drug Price Negotiation Program” and sets certain new policies for the program and for Medicare Part D, as the Inflation Reduction Act of 2022 requires. (91 FR 72176, Summary)
- From guidance to regulation. CMS says it is “codifying, with limited modification,” policies it had set out in program guidance, by adding a new part 429 to Title 42 of the Code of Federal Regulations and changing part 423 (the Part D rules). (Section I.A.2)
- Combination drugs. A new policy for specific fixed-combination drugs that CMS decides are new formulations of existing drugs: CMS will look at all dosage forms and strengths of the shared active ingredient from the same manufacturer when identifying a drug that qualifies for negotiation. (§ 429.125(b)(4)(ii))
- Orphan drugs. Clarifies how CMS counts the 7- and 11-year periods since approval for drugs that used to qualify for the orphan drug exclusion. (§ 429.125(c)(3)(i))
- Generics and biosimilars. Sets the process and schedule for deciding whether a generic or biosimilar maker is engaged in “bona fide marketing.” (§ 429.130)
- One-time treatments. Explains how CMS calculates a 30-day equivalent supply for drugs given one time, such as some vaccines, gene therapies and cancer therapies. (§§ 429.415(a)(2), 429.510(d)(2)(ii))
- Small biotech floor. Explains how a temporary price floor for small biotech drugs will work for price years 2029 and 2030, with a modified step-by-step method for calculating the ceiling. (§ 429.440)
- Renegotiation and off-label use. Clarifies when off-label use is considered for renegotiation eligibility and selection. (§§ 429.605, 429.610)
- Company sales. Adds details on how a manufacturer can transfer its program responsibilities to a company that acquires the drug. (§ 429.210(c))
What it means for Part D coverage
CMS finalized, as proposed, a requirement that for each year a selected drug has a maximum fair price in effect, Part D plan sponsors must include that drug on their formularies, covering all dosage forms and strengths that are Part D drugs and for which the price is in effect. (§ 423.120(b)(2)(vii)–(viii); Final Decision, Section II)
Some commenters said that being on a formulary does not guarantee affordable access, for example if a plan uses a less favorable tier, prior authorization or step therapy. The comments and CMS’s responses are in the preamble of the final rule. (Section II, comments and responses)
When it applies
- Effective: December 5, 2026.
- Applicability: to the Negotiation Program beginning with initial price applicability year 2029 and to Part D coverage beginning January 1, 2029. Unless otherwise specified, this includes selecting drugs and negotiating prices for 2029, which will take place during calendar year 2027.
- Drugs for 2026–2028: CMS says its program guidance for those years “remains applicable and is not superseded” by this rule; the rule’s provisions apply to those drugs starting in 2029.
(91 FR 72176, Dates; Section I.A.2)
What it means in South Carolina
- This is a federal rule that applies the same way in every state. We did not find anything in it specific to South Carolina.
- It mainly sets how CMS and drug manufacturers carry out the program. Its direct requirements for plans concern Part D sponsors’ formularies. People with Medicare drug coverage do not need to take any action because of this rule.
Current status
Final rule published November 9, 2026; effective December 5, 2026; applies starting with the 2029 price year and Part D coverage beginning January 1, 2029. (91 FR 72176)
Sources
- Federal Register: “Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program,” final rule, 91 FR 72176, FR Doc. 2026-22792 (Nov. 9, 2026)
- CMS: Medicare Drug Price Negotiation Program Final Guidance, Initial Price Applicability Year 2028 (Sept. 30, 2025)
Get the next explainer in your inbox
South Carolina and federal laws, explained in plain English. One email a week: what changed and what it means for you. Confirm your address and get the free South Carolina 2026-27 Law Guide (PDF).
Free. Nonpartisan. Unsubscribe anytime. We'll email you a link to confirm. Privacy policy
Every statement above is drawn from the official source text linked here; section references are shown in grey. This is a plain-English summary, not legal advice. Spot an error? Tell us.